{"generic":"Hyaluronate Sodium","drugs":["Biolon","Bionect","Euflexxa","Hyalgan","Hyalgan L\/L","Hyaluronate Sodium","Hylira","Provisc","Shellgel"],"mono":{"0":{"id":"bx83s0","title":"Generic Names","mono":"Hyaluronate Sodium"},"1":{"id":"bx83s1","title":"Dosing and Indications","sub":{"0":{"id":"bx83s1b4","title":"Adult Dosing","mono":"<ul><li><b>Cataract surgery; Adjunct:<\/b> a sufficient amount of sodium hyaluronate is slowly and carefully introduced (using a cannula or needle) into the anterior chamber; injection can be performed either before or after delivery of the lens<\/li><li><b>Corneal transplant; Adjunct:<\/b> the anterior chamber is filled with hyaluronate sodium after removal of the corneal button; the donor graft can then be placed on top of the bed of hyaluronate sodium and sutured in place; additional hyaluronate sodium may be injected to replace what is lost as a result of surgical manipulation<\/li><li><b>Filtering operation on eye; Adjunct:<\/b> following performance of the trabeculectomy, inject slowly and carefully through a corneal paracentesis to reconstitute the anterior chamber; further injection of Healon(R) can be continued to allow it to extrude into the subconjunctival filtration site through and around the sutured outer scleral flap<\/li><li><b>Insertion of intraocular lens; Adjunct:<\/b> a sufficient amount of sodium hyaluronate is slowly and carefully introduced (using a cannula or needle) into the anterior chamber; injection can be performed either before or after delivery of the lens<\/li><li><b>Operative procedure on anterior chamber of eye; Adjunct:<\/b> a sufficient amount of sodium hyaluronate is slowly and carefully introduced (using a cannula or needle) into the anterior chamber; injection can be performed either before or after delivery of the lens<\/li><li><b>Osteoarthritis of knee:<\/b> Euflexxa(R), inject 20 mg per 2 mL (contents of prefilled syringe) INTRA-ARTICULARLY into the knee at weekly intervals for 3 weeks<\/li><li><b>Osteoarthritis of knee:<\/b> Gel-One(R), inject 30 mg per 3 mL (contents of prefilled syringe) INTRA-ARTICULARLY into the knee<\/li><li><b>Osteoarthritis of knee:<\/b> Hyalgan(R), inject 20 mg per 2 mL (contents of prefilled syringe) INTRA-ARTICULARLY into the knee once weekly for a total of 5 injections<\/li><li><b>Osteoarthritis of knee:<\/b> Supartz(R), inject 25 mg per 2.5 mL (contents of prefilled syringe) INTRA-ARTICULARLY into the knee once weekly for a total of 5 injections<\/li><li><b>Osteoarthritis of knee:<\/b> Synvisc(R), inject 16 mg per 2 mL (contents of prefilled syringe) INTRA-ARTICULARLY into the knee once weekly for a total of 3 injections<\/li><li><b>Retinal detachment repair; Adjunct:<\/b> sodium hyaluronate is slowly introduced into the vitreous cavity; by directing the injection, sodium hyaluronate can be used to separate membranes (eg, epiretinal membranes) away from the retina for safe excision and release of traction<\/li><li><b>Subacromial impingement, Syndrome of the shoulder:<\/b> 20 mg INJECTION into subacromial space once weekly for 3 weeks was used in a clinical trial (n=80)<\/li><li><b>Wound:<\/b> Clean and disinfect wound\/ulcer prior to treatment, then apply a thin layer to affected area(s) 2 or 3 times per day; cover area with a sterile gauze pad and, if needed, with an elastic or compressive bandage<\/li><\/ul>"},"1":{"id":"bx83s1b5","title":"Pediatric Dosing","mono":"<ul><li>safety and effectiveness of intraocular injection in children have not been established<\/li><li>safety and efficacy of intra-articular injection in pediatric patients have not been established, including patients younger than 21 years<\/li><\/ul>"},"3":{"id":"bx83s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Cataract surgery; Adjunct<\/li><li>Corneal transplant; Adjunct<\/li><li>Filtering operation on eye; Adjunct<\/li><li>Insertion of intraocular lens; Adjunct<\/li><li>Operative procedure on anterior chamber of eye; Adjunct<\/li><li>Osteoarthritis of knee<\/li><li>Retinal detachment repair; Adjunct<\/li><li>Wound<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Arthropathy - Disorder of shoulder<\/li><li>Intravitreal tamponade<\/li><li>Keratoconjunctivitis sicca<\/li><li>Subacromial impingement, Syndrome of the shoulder<\/li><\/ul>"}}},"2":{"id":"bx83s2","title":"Black Box Warning","mono":"<b>Intraocular (Solution)<\/b><br\/>This product contains dry natural rubber (Provisc(R)).<br\/>"},"3":{"id":"bx83s3","title":"Contraindications\/Warnings","sub":[{"id":"bx83s3b9","title":"Contraindications","mono":"<ul><li>hypersensitivity to hyaluronate preparations (Hyalgan(R), Hylira(R), Provisc(R))<\/li><li>knee joint infections or skin disease at injection site, active (Hyalgan(R))<\/li><\/ul>"},{"id":"bx83s3b10","title":"Precautions","mono":"<ul><li>allergic and anaphylactic reactions have been reported (Hyalgan(R))<\/li><li>allergic reactions may occur due to potential for minute amounts of protein in the preparation (Provisc(R))<\/li><li>allergy to avian or avian-derived products, including eggs, feathers, or poultry; use caution (Hyalgan(R))<\/li><li>aphakic diabetic patients undergoing posterior segment procedures; avoid using large amounts of sodium hyaluronate (Healon(R))<\/li><li>concomitant use of disinfectants containing quarternary ammonium salts should be avoided (hyaluronic acid can precipitate in their presence) (Hyalgan(R)))<\/li><li>elevated intraocular pressure, postoperative, has been reported; avoid overfilling anterior or posterior segment of eye and insure complete removal of hyaluronate sodium from eye after procedure (Healon(R), Healon5(R), HealonGV(R), Provisc(R), Shellgel(R))<\/li><li>elevated intraocular pressure, preoperative, may exacerbate condition postoperatively (Healon5(R), HealonGV(R))<\/li><li>glaucoma, preexisting, or compromised outflow; postoperative intraocular pressure may be elevated (Healon(R), Healon5(R), Healon GV(R), Shellgel(R))<\/li><li>increased inflammation in the injected knee, transient, has been reported in some patients with inflammatory arthritis (ie, rheumatoid or gouty arthritis) (Hyalgan(R))<\/li><\/ul>"},{"id":"bx83s3b11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"bx83s3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"bx83s5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Musculoskeletal:<\/b>Injection site pain (23%)<br\/><b>Serious<\/b><ul><li><b>Musculoskeletal:<\/b>Pseudogout, Septic arthritis<\/li><li><b>Ophthalmic:<\/b>Raised intraocular pressure, Postoperative, likely if hyaluronate not removed as completely as possible after surgery<\/li><li><b>Other:<\/b>Inflammatory disorder, Postoperative, including iritis, hypopyon, endophthalmitis (rare)<\/li><\/ul>"},"6":{"id":"bx83s6","title":"Drug Name Info","sub":{"0":{"id":"bx83s6b17","title":"US Trade Names","mono":"<ul><li>Biolon<\/li><li>Bionect<\/li><li>Euflexxa<\/li><li>Hyalgan<\/li><li>Hyalgan L\/L<\/li><li>Hylira<\/li><li>Provisc<\/li><li>Shellgel<\/li><\/ul>"},"2":{"id":"bx83s6b19","title":"Class","mono":"<ul><li>Cartilaginous Defect Repair Agent<\/li><li>Dermatological Agent<\/li><li>Keratolytic<\/li><li>Ophthalmologic Agent<\/li><li>Protectant, Dermatological<\/li><li>Surgical Aid, Ocular<\/li><li>Wound Care Agent<\/li><\/ul>"},"3":{"id":"bx83s6b20","title":"Regulatory Status","mono":"RX\/OTC<br\/>"},"4":{"id":"bx83s6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"bx83s7","title":"Mechanism Of Action","mono":"Sodium hyaluronate forms a viscoelastic solution in water that assists in absorbing mechanical stress and provides a protective buffer for tissues and acts as a protective transport vehicle.<br\/>"},"9":{"id":"bx83s9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>vial\/syringe is intended for single use; use immediately after opening and discard unused contents<br\/><\/li><li><b>Intra-articular<\/b><br\/><ul><li>do not prepare skin with quaternary ammonium salt disinfectant; may cause precipitation of product<\/li><li>injection of subQ lidocaine or similar local anesthetic prior to injection of product  may be performed<\/li><li>remove joint effusion prior to injection; use separate syringes for removing fluid and for injection, but use the same needle<\/li><li>recommended needle size for prefilled syringe: Euflexxa, 17- to 21-mm gauge; Gel-One(R), 18- to 20-gauge, Hyalgan(R), 20-gauge; Supartz(R), 22- to 23-gauge; Synvisc(R), 18- to 22-gauge<\/li><li>vials\/syringes are for single-use only; use immediately after opening container<\/li><li>use separate vial\/syringe for treatment of bilateral knee<\/li><\/ul><\/li><li><b>Ophthalmic<\/b><br\/><ul><li>(ProVisc(R) prefilled syringe) use syringe assembly for injection only; use for aspiration is not advised<\/li><li>(ProVisc(R) prefilled syringe) do not attach delivery system to instruments other than the one provided<\/li><li>allow solution to come to room temperature (approximately 20 to 40 minutes) prior to use<\/li><li>irrigation\/aspiration should be used to create a fluid-filled space above the lens before initiating phacoemulsification (Healon5(R))<\/li><li>use solution only if clear; if cloudiness or precipitation is observed, remove cloudy or precipitated material by irrigation and\/or aspiration<\/li><li>avoid reuse of cannulas; if necessary, rinse cannula thoroughly with sterile distilled water<\/li><li>express small amount from syringe prior to use and examine for particulate matter, specifically rubber particles<\/li><li>avoid trapping air bubbles behind sodium hyaluronate (Healon(R))<\/li><li>at the close of surgery, completely remove sodium hyaluronate from anterior chamber by irrigation or aspiration; do not overfill the anterior chamber<\/li><\/ul><\/li><\/ul>"},"10":{"id":"bx83s10","title":"Monitoring","mono":"<ul><li>ophthalmic surgical aid (ocular injection): reduced trauma to corneal endothelium and surrounding tissue<\/li><li>osteoarthritis of the knee (intra-articular): improved range of motion, decreased early morning stiffness and painful\/swollen joint(s)<\/li><li>(ocular injection): intraocular pressure; during anterior segment ophthalmic procedures<\/li><\/ul>"},"11":{"id":"bx83s11","title":"How Supplied","mono":"<ul><li><b>Amvisc<\/b><br\/>Intraocular Solution: 12 MG\/ML<br\/><\/li><li><b>Amvisc Plus<\/b><br\/>Intraocular Solution: 16 MG\/ML<br\/><\/li><li><b>Bionect<\/b><br\/><ul><li>Topical Cream: 0.2 %<\/li><li>Topical Gel\/Jelly: 0.2 %<\/li><\/ul><\/li><li><b>Euflexxa<\/b><br\/>Injection Solution: 10 MG\/ML<br\/><\/li><li><b>Gel-One<\/b><br\/>Injection Gel\/Jelly: 30 MG\/3 ML<br\/><\/li><li><b>Hyalgan<\/b><br\/>Injection Solution: 10 MG\/ML<br\/><\/li><li><b>HyGel<\/b><br\/>Topical Gel\/Jelly: 0.2 %<br\/><\/li><li><b>Hylira<\/b><br\/><ul><li>Topical Gel\/Jelly: 0.2 %<\/li><li>Topical Lotion: 0.1 %<\/li><\/ul><\/li><li><b>Provisc<\/b><br\/>Intraocular Solution: 10 MG\/ML<br\/><\/li><li><b>Supartz<\/b><br\/>Injection Solution: 10 MG\/ML<br\/><\/li><\/ul>"},"13":{"id":"bx83s13","title":"Clinical Teaching","mono":"<ul><li>Advise patients receiving the intra-articular formulation, to avoid stressful, prolonged, or weight-bearing activities on the affected joint for at least 48 h after injection.<\/li><li>Patients receiving the intra-articular formulation should report signs\/symptoms of infection at injection site.<\/li><\/ul>"}}}